statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance Blueprint Medicines Reports Strong First Quarter 2024 Results and...

Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT/AYVAKYT (avapritinib) Full Year Revenue Guidance

Latest Ratings for BPMC
 DateFirmActionFromTo Mar 2022StifelMaintainsBuy Mar 2022CitigroupInitiates Coverage OnNeutral Feb 2022SVB LeerinkDowngradesOutperformMarket Perform
 View More Analyst...

The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 PR Newswire...

Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics Blueprint Medicines to Host Webcast and Conference Call Highlighting...

Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics

Shares of Blueprint Medicines Co. (NASDAQ:BPMC - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports...

Brokerages Set Blueprint Medicines Co. (NASDAQ:BPMC) PT at $85.43

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire CAMBRIDGE, Mass...

Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Blueprint Medicines Corp (BPMC) was identified as having a larger market cap than the smaller end of the...

Blueprint Medicines Larger Than S&P 500 Component VFC

Blueprint Medicines Co. (NASDAQ:BPMC  Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the stock in a transaction on Thursday, March 7th. The shares were sold at an average...

Insider Selling: Blueprint Medicines Co. (NASDAQ:BPMC) Director Sells $1,000,582.77 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC  Get Free Report) Director Jeffrey W. Albers sold 11,033 shares of the firms stock in a transaction dated Thursday, March 7th. The shares were sold...

Jeffrey W. Albers Sells 11,033 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) Stock

This price move could be a signal that BPMC may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Blueprint Medicines (BPMC, $94.79) price may drop as it broke higher Bollinger Band on Mar 27, 2024

Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Volume	2M
52-Wk High	$101.00
52-Wk Low	$43.89

Period	Estimated	Reported	Surprise	Result
Q2'24	-$1.46	--	--	N/A
Q1'24	-$1.67	$1.45	187.01%	BEAT
Q4'23	-$2.04	-$1.82	10.89%	BEAT
Q3'23	-$2.37	-$2.20	7.07%	BEAT
Q2'23	-$2.52	-$2.19	13.03%	BEAT

BPMC Blueprint Medicines Corp

About

Feed

News

Sentiment

Earnings

Fundamentals